Last updated: February 23, 2026
What is NDC 72205-0096?
NDC 72205-0096 refers to a specific drug product listed in the National Drug Code (NDC) database. It corresponds to Xywav, a calcium, magnesium, potassium, and sodium oxybate formulation approved by the FDA for the treatment of narcolepsy and idiopathic hypersomnia. The drug is marketed by Jazz Pharmaceuticals.
Market Size and Demand Drivers
Market Scope
The primary market for NDC 72205-0096 (Xywav) is in the treatment of narcolepsy and idiopathic hypersomnia, both considered rare neurological disorders.
Patient Population
- Narcolepsy prevalence: Approximately 0.03% to 0.05% of the U.S. population (~1.2 million people) [1].
- Idiopathic hypersomnia: Estimated at 10-15% of narcolepsy cases; prevalence roughly 0.003% to 0.007% [2].
Competitive Landscape
- Main competitors include Sodium Oxybate (Xyrem), also by Jazz Pharmaceuticals.
- Recent annual sales of Xyrem have exceeded $600 million in the U.S. [3].
Market Penetration
- Xywav, approved in 2020, gained rapid adoption due to a better side-effect profile relative to Xyrem.
- As of 2022, Xywav's U.S. sales exceeded $200 million [4].
Pricing Overview
Current List Price
- Xyrem: Approximate wholesale acquisition cost (WAC) per treatment month: $70,000.
- Xywav: Slightly lower WAC per month, around $65,000, owing to dosage differences and formulary strategies [5].
Pricing Strategy
- Both drugs are priced significantly higher than typical pharmaceuticals, dictated by the rare disease status and lack of generic competition.
- Reimbursement is primarily through Medicare, Medicaid, and private insurance.
Comparison with Similar Drugs
| Drug |
Approved Indication |
List WAC per Month |
Marketed by |
| Xyrem |
Narcolepsy, Cataplexy |
$70,000 |
Jazz Pharmaceuticals |
| Xywav |
Narcolepsy, Idiopathic Hypersomnia |
$65,000 |
Jazz Pharmaceuticals |
Price Projections (Next 3-5 Years)
Assumptions
- Moderate annual growth rate of 3-5% driven by increased adoption, expanded indications, and inflation.
- No generic competition released within the forecast period due to patent protections and regulatory barriers.
- The potential expansion of approved indications (e.g., off-label uses) could boost sales.
Projections
| Year |
Estimated U.S. Sales |
Estimated Monthly Cost |
Remarks |
| 2023 |
$250 million |
$65,000 |
Baseline, rising patient awareness |
| 2025 |
$330 million |
$68,000 |
Increased adoption and off-label use |
| 2027 |
$430 million |
$72,000 |
Market expansion, inflation adjustments |
Factors Influencing Price
- Regulatory actions (e.g., potential price caps for specialty drugs).
- Healthcare policy shifts toward value-based pricing.
- Competitive entry if generics or biosimilars emerge.
Regulatory and Market Risks
- Patent challenges could threaten exclusivity.
- Insurance reimbursement policies could cap prices or restrict access.
- New treatment options or generics could lower prices and sales.
Key Takeaways
- NDC 72205-0096 (Xywav) sees annual U.S. sales nearing $250 million, with growth prospects driven by expanding indications and high disease prevalence.
- Price per month remains high compared to average pharmaceuticals, reflecting the rarity of the conditions.
- Market growth hinges on adoption rates, reimbursement policies, and regulatory status.
- Price projections indicate a 3-5% annual increase over the next five years, barring significant market disruptions.
- Competitive threats and regulatory changes pose long-term risks to pricing stability.
FAQs
1. How does Xywav differ from Xyrem?
Xywav has a lower sodium content, reducing cardiovascular risks, and is indicated for narcolepsy and idiopathic hypersomnia, whereas Xyrem is primarily for narcolepsy with cataplexy.
2. What factors influence the high drug prices?
Purposeful pricing reflects the rarity of the disorders, lack of available alternatives, high R&D costs, and regulatory hurdles.
3. Is there potential for price reduction?
Price reductions are unlikely without generic entry or regulatory intervention, given current market exclusivity and demand.
4. Are there alternative treatments for narcolepsy?
Current treatments include other stimulants and wake-promoting agents, but sodium oxybate remains a standard due to efficacy.
5. What are the regulatory challenges facing this drug?
Patent challenges, international regulation changes, and safety concerns could impact market exclusivity and pricing.
References
[1] National Institute of Neurological Disorders and Stroke (2021). Narcolepsy fact sheet.
[2] American Academy of Sleep Medicine (2020). Prevalence estimates of hypersomnia.
[3] IQVIA (2022). U.S. pharmaceutical sales data.
[4] Jazz Pharmaceuticals (2022). Annual Financial Report.
[5] GoodRx (2023). Prescription drug prices.
